Harry H. Penner, Jr., J.D., L.L.M.

Mr. Penner has been a director of Celldex since the merger in March 2008 between Celldex and AVANT Immunotherapeutics and had been a director of AVANT since January 1997. In 2001, he founded Nascent BioScience, a firm engaged in the creation and development of new biotechnology companies, where he served as Chairman and Chief Executive Officer from 2001 to June 2023. From 1993 to 2001, Mr. Penner was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation. From 1985 to 1993, he was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and from 1985 to 1988 as the company’s Executive Vice President and General Counsel in Denmark. In addition to having served on the board of directors of several public and privately held life science companies, Mr. Penner is currently Chair of Neurocyte Therapeutics, Inc. He has served as BioScience Advisor to the Governor and the State of Connecticut, Chair of BioCT, Chair of the Connecticut Board of Governors of Higher Education and Chair of the Connecticut Technology Council. Mr. Penner received a B.A. from the University of Virginia, a J.D. from Fordham University and an L.L.M. in International Law from New York University.